Furthermore, a randomized, open-label study compared cabozantinib, an oral small-molecule inhibitor of tyrosine kinases, with everolimus in patients with advanced clear cell renal cell carcinoma that had progressed after VEGFR-targeted therapy [51]. Here, KDR is linked to clear cell renal carcinoma.